CSIMarket
 
Compass Pathways Plc  (CMPS)
Other Ticker:  
 
 
Price: $9.9000 $0.11 1.072%
Day's High: $9.98 Week Perf: -7.22 %
Day's Low: $ 9.74 30 Day Perf: -4.99 %
Volume (M): 376 52 Wk High: $ 12.75
Volume (M$): $ 3,724 52 Wk Avg: $8.48
Open: $9.90 52 Wk Low: $5.01



 Market Capitalization (Millions $) 506
 Shares Outstanding (Millions) 51
 Employees 76
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -118
 Cash Flow (TTM) (Millions $) 77
 Capital Exp. (TTM) (Millions $) 0

Compass Pathways Plc
Compass Pathways Plc is a UK-based pharmaceutical company focused on the development of innovative therapies for mental health patients. The company was founded in 2016 and is headquartered in London, UK. Compass Pathways is a leader in the field of psychedelic-assisted therapy, a promising new approach to the treatment of depression and other mental health disorders using psychedelic compounds.

The company's flagship product is a synthetic form of psilocybin, the psychoactive compound found in magic mushrooms. Compass Pathways has completed a phase 2 clinical trial of this product in patients with treatment-resistant depression, and is currently planning to initiate a phase 3 trial. The company is also pursuing other drug development programs, including a proprietary formulation of ketamine.

Compass Pathways has a highly experienced management team, led by co-founder and CEO George Goldsmith. The company has a strong financial position, with over $150 million in funding from investors, including the venture arms of tech giants like Peter Thiel, Bill Gates, and Jeff Bezos. In 2020, the company went public on the Nasdaq stock exchange with a valuation of over $1 billion.

Compass Pathways is committed to scientific rigor and safety in the development of psychedelic-assisted therapies. The company has formed partnerships with leading academic institutions and research organizations to conduct trials and gather data on the safety and efficacy of these therapies. Compass Pathways is also focused on building a sustainable business model that ensures broad access to these therapies for patients in need.

Overall, Compass Pathways is a pioneering company in the emerging field of psychedelic-assisted therapy, with a bold vision for improving mental health outcomes through innovative drug development and clinical research.


   Company Address: 33 Broadwick Street London 0
   Company Phone Number: 676-6461   Stock Exchange / Ticker: NASDAQ CMPS
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Compass Pathways Plc

Compass Pathways Plc Reports Impressive Fourth Quarter Efforts Amidst Industry Growth

Compass Pathways Plc, a biotechnology company focused on mental health innovation, has experienced significant growth in its share price over the past year. According to recent financial results, the company's shares have risen by 24.72% compared to a year ago, reaching an impressive 69.55% increase in the past 90 days alone. This positive trend is further supported by the fact that Compass Pathways Plc shares are currently trading on the NASDAQ at a significant 22.4% above its 52-week average.
One factor that could potentially contribute to this growth is the company's collaboration with Hackensack Meridian Health (HMH) to optimize the clinical model for COMP360 psilocybin treatment, a psychedelic substance found in magic mushrooms. This collaboration aims to develop an effective treatment model if approved by the FDA, highlighting Compass Pathways' commitment to innovative mental health solutions.

Partnership

Forging a Path to Transformative Mental Health: Compass Pathways and Hackensack Meridian Health Collaborate to Optimize COMP360 Psilocybin Treatment Delivery Model

Published Tue, Jan 16 2024 1:00 PM UTC

Compass Pathways and Hackensack Meridian Health Collaborate to Optimize Clinical Model for COMP360 Psilocybin TreatmentIn recent years, there has been a growing interest in the potential therapeutic benefits of psychedelic substances for mental health conditions. One such substance is psilocybin, the active component found in magic mushrooms. Recognizing the need for innovat...

Partnership

Trailblazing Collaboration: Compass Pathways and Greenbrook TMS Join Forces for Scalable Psilocybin Treatment Delivery Models, Eyeing Disruptive Progress in Mental Health Therapeutics

Published Fri, Jan 5 2024 1:00 PM UTC

In a paradigm-shifting development for the global mental health therapeutics sector, Compass Pathways Plc (Compass), a British mental health company dealing in research and development of therapeutics has entered into a ground-breaking three-year research collaboration with Greenbrook TMS, one of North America's leading outpatient mental health service providers. The collabo...

Clinical Study

Psilocybin under a New Light: Compass Pathways Plc's COMP360 Clears Phase 2 Safety Hurdle, Poses Potential for Mental Healthcare Breakthrough

Published Tue, Dec 19 2023 9:05 PM UTC


Compass Pathways Plc, the healthcare innovator renowned for its investigation into the potential benefits of psychedelic substances for mental health, has shared promising updates on its phase 2 study with COMP360 psilocybin treatment for post-traumatic stress disorder (PTSD).
The promising news that COMP360 was well-tolerated in this phase 2 study is an exciting de...

Clinical Study

Unlocking the Power of Psilocybin: A Paradigm Shift in Bipolar II Depression Treatment

Published Wed, Dec 6 2023 9:01 PM UTC



In a groundbreaking development within the field of mental health, the results of a recent study on psilocybin treatment for bipolar II depression have been published in JAMA Psychiatry. This pioneering research signifies a major milestone, as it is believed to be the first-ever clinical trial exploring the therapeutic effects of psilocybin on this specific mental ...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com